SWEDESBORO, N.J.--(BUSINESS WIRE)--Today, Wedgewood announces the addition of molnupiravir to its formulary. Originally developed for human viral infections, including COVID-19, molnupiravir has emerged as a promising option for both first- and second-line therapy of Feline Infectious Peritonitis (FIP).

新泽西州斯维德斯伯罗（商业新闻短讯）——今天，威奇伍德宣布将莫那匹拉韦加入其处方集。molnupiravir最初是为人类病毒感染（包括新型冠状病毒肺炎）开发的，已成为猫科感染性腹膜炎（FIP）一线和二线治疗的有希望的选择。

This often-fatal disease affects an estimated 15,000 US cats each year, posing a significant concern for veterinarians and cat owners alike..

这种通常致命的疾病每年影响大约15000只美国猫，这对兽医和猫主人都构成了极大的担忧。。

Wedgewood will be the first US veterinary compounding pharmacy to offer feline-friendly formulations of molnupiravir in a variety of doses designed to combat the different forms of FIP (Effusive, Non-effusive, Neurological, and Ocular):

Wedgewood将是美国第一家兽医复方药店，提供各种剂量的猫科动物友好型莫那匹拉韦配方，旨在对抗不同形式的FIP（渗出性，非渗出性，神经性和眼部）：

50mg/ml and 100mg/ml Flavored Oral Oil Suspensions

50mg/ml和100mg/ml风味口服油混悬液

25mg, 40mg, 50mg, 60mg, 70mg and 80mg Capsules

25mg、40mg、50mg、60mg、70mg和80mg胶囊

In late 2023, Wedgewood’s product team met with FIP Global Cats to explore treatment options under study for FIP. Two key studies prompted Wedgewood to pursue molnupiravir. Dr. Okihiro Sase of the You-Me Animal Clinic in Japan reported substantial remission in the majority of 18 cats treated with molnupiravir, with minimal side effects.

2023年末，威奇伍德的产品团队与FIP Global Cats会面，探讨正在研究的FIP治疗方案。两项关键研究促使威奇伍德寻求莫那匹拉韦。日本You Me动物诊所的Okihiro Sase博士报告说，接受莫那匹拉韦治疗的18只猫中，大多数都得到了实质性缓解，副作用最小。

This study aligns with other research efforts, including another by Meagan Roy, Nicole Jacque, Wendy Novicoff, Emma Li, Rosa Negash, and Samantha J. M. Evans, underscoring molnupiravir’s potential as both a primary and rescue treatment for FIP. Wedgewood notes that its molnupiravir formulation is not the same as the drug used in these studies and makes no claims of safety or efficacy of it molnupiravir formulation..

这项研究与其他研究工作相一致，包括Meagan Roy，Nicole Jacque，Wendy Novicoff，Emma Li，Rosa Negash和Samantha J.M.Evans的另一项研究，强调了molnupiravir作为FIP的主要和救援治疗的潜力。Wedgewood指出，它的molnupiravir制剂与这些研究中使用的药物不同，并且没有声称它的molnupiravir制剂的安全性或有效性。。

Dr. Alejandro Bernal, DVM and CEO of Wedgewood, emphasized the impact of this launch: 'At Wedgewood, we are always looking for innovative treatment options that truly make a difference. The introduction of molnupiravir for FIP is a significant step forward in addressing an often-devastating disease.

威奇伍德的DVM兼首席执行官亚历杭德罗·伯纳尔博士强调了此次发布的影响：“在威奇伍德，我们一直在寻找真正与众不同的创新治疗方案。为FIP引入莫那维拉韦是解决一种通常具有破坏性的疾病的重要一步。

By offering feline-friendly formulations like fish- and chicken-flavored oral liquids, we are giving veterinarians more tools to help their patients recover and improve their quality of life. We’re excited to see the impact this treatment will have on the cats and pet owners we serve.'.

通过提供鱼类和鸡肉味口服液等对猫友好的配方，我们为兽医提供了更多工具，帮助他们的患者康复并提高生活质量。。

Nicole Jacque, Co-Founder of FIP Global CATS, added, “The availability of compounded molnupiravir marks a significant advancement in FIP treatment for cats in the US. With its proven safety and efficacy in both published and ongoing studies, molnupiravir has already demonstrated its value in countries where it's legally available, notably in curbing the FIP outbreak in Cyprus.

FIP Global CATS联合创始人妮可·雅克（NicoleJacque）补充道：“复合莫那匹拉韦的上市标志着美国猫用FIP治疗取得了重大进展。莫那匹拉韦在已发表和正在进行的研究中均证明了其安全性和有效性，已在合法可用的国家证明了其价值，特别是在遏制塞浦路斯FIP疫情方面。

Critically, it serves as a vital rescue option for cats that may have developed resistance to other antivirals. FIP Global CATS is elated that US veterinarians and cat owners now have access to this powerful treatment. We're confident this development brings us closer to our goal of making safe, effective, and affordable regulated FIP treatment the standard of care worldwide.”.

至关重要的是，它是可能对其他抗病毒药物产生耐药性的猫的重要救援选择。FIP Global CATS很高兴美国兽医和猫主人现在可以使用这种强大的治疗方法。。

Wedgewood’s molnupiravir is available in dosages of 10-20 mg/kg, consistent with international veterinary research and tailored to meet the individual needs of feline patients. This individualized approach ensures that each cat receives the best possible chance for recovery.

Wedgewood的molnupiravir的剂量为10-20 mg/kg，与国际兽医研究一致，并根据猫患者的个人需求量身定制。这种个性化的方法确保每只猫都有最好的康复机会。

For more details on Molnupiravir and access to educational resources please visit www.Wedgewood.com/molnupiravir.

有关Molnupiravir的更多详细信息以及获取教育资源的途径，请访问www.Wedgewood.com/Molnupiravir。

About Wedgewood:

关于Wedgewood：

Wedgewood is the nation’s largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually.

威奇伍德是美国最大、最值得信赖的复合兽药供应商。它的下一代家庭递送平台Blue Rabbit简化了患者护理，标志着在线药房服务的重大发展。蓝兔和威奇伍德每年为70000多名兽医专业人员和100多万只动物提供服务。

For more information visit www.Wedgewood.com..

For more information visit www.Wedgewood.com..

About FIP Global Cats:

关于FIP全球猫：

FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research.

FIP Global CATS®（社区，倡导，治疗，支持）是抗击猫传染性腹膜炎（FIP）的领先组织。联合兽医、研究人员和宠物主人，它为那些面临FIP诊断的人提供了至关重要的支持。该组织致力于赋予宠物父母权力，倡导安全，有效和负担得起的法律治疗，并推进FIP研究。

For more information, please visit https://www.fipglobalcats.com/..

For more information, please visit https://www.fipglobalcats.com/..